Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + PD-1 Antibody as Maintenance Therapy in First-line Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT07783321Phase 3Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2033
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Progression-Free Survival at 24 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07783321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783321.